Cargando…
Prognostic impact of elevated fatty acid‐binding protein 1 in patients with heart failure
AIMS: Few biomarkers to evaluate pathophysiological changes in extra‐cardiac tissues have been identified in patients with heart failure (HF). Fatty acid‐binding protein 1 (FABP), also known as liver FABP, is predominantly expressed in the liver. Circulating FABP1 has been proposed to be a sensitive...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006713/ https://www.ncbi.nlm.nih.gov/pubmed/33539661 http://dx.doi.org/10.1002/ehf2.13239 |
_version_ | 1783672362273603584 |
---|---|
author | Kagami, Kazuki Sunaga, Hiroaki Sorimachi, Hidemi Harada, Tomonari Yoshida, Kuniko Kato, Toshimitsu Kurosawa, Koji Kawakami, Ryo Koitabashi, Norimichi Iso, Tatsuya Adachi, Takeshi Kurabayashi, Masahiko Obokata, Masaru |
author_facet | Kagami, Kazuki Sunaga, Hiroaki Sorimachi, Hidemi Harada, Tomonari Yoshida, Kuniko Kato, Toshimitsu Kurosawa, Koji Kawakami, Ryo Koitabashi, Norimichi Iso, Tatsuya Adachi, Takeshi Kurabayashi, Masahiko Obokata, Masaru |
author_sort | Kagami, Kazuki |
collection | PubMed |
description | AIMS: Few biomarkers to evaluate pathophysiological changes in extra‐cardiac tissues have been identified in patients with heart failure (HF). Fatty acid‐binding protein 1 (FABP), also known as liver FABP, is predominantly expressed in the liver. Circulating FABP1 has been proposed to be a sensitive biomarker for liver injury. However, little is known about the potential role of FABP1 as a biomarker for HF. METHODS AND RESULTS: Measurements of serum FABP1 and echocardiography were performed in subjects with compensated HF (n = 162) and control subjects without HF (n = 20). Patients were prospectively followed‐up for a composite outcome of all‐cause mortality or HF hospitalization. Compared with control subjects, levels of FABP1 were elevated in HF patients [7.9 (6.4–11.7) vs. 17.6 (10.4–28.9) ng/mL, P < 0.0001]. There were significant correlations between FABP1 levels and estimated right ventricular systolic pressure and right atrial pressure. During a median follow‐up of 12.0 months, there were 55 primary composite endpoints in the HF cohort. The highest FABP1 tertile was associated with a three‐fold increased risk of the composite outcome compared with the lowest tertile [95% confidence interval (1.46–6.68), P = 0.003], but other conventional hepatobiliary markers did not predict the outcome. After adjusting for age, sex, atrial fibrillation, and N‐terminal pro‐B‐type natriuretic peptide levels, serum FABP1 remained independently associated with the outcome. Adding FABP1 to the model based on clinical factors and N‐terminal pro‐B‐type natriuretic peptide significantly improved the prognostic value (global χ (2) 20.8 vs. 15.5, P = 0.01). CONCLUSION: Serum FABP1 levels are elevated in compensated HF patients, and the magnitude of elevation is independently associated with pulmonary hypertension, right atrial hypertension, and worse clinical outcomes. FABP1 may serve as a new potential biomarker for the assessment of hitherto unrecognized derangement of cardio‐hepatic interaction in HF. |
format | Online Article Text |
id | pubmed-8006713 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80067132021-04-01 Prognostic impact of elevated fatty acid‐binding protein 1 in patients with heart failure Kagami, Kazuki Sunaga, Hiroaki Sorimachi, Hidemi Harada, Tomonari Yoshida, Kuniko Kato, Toshimitsu Kurosawa, Koji Kawakami, Ryo Koitabashi, Norimichi Iso, Tatsuya Adachi, Takeshi Kurabayashi, Masahiko Obokata, Masaru ESC Heart Fail Original Research Articles AIMS: Few biomarkers to evaluate pathophysiological changes in extra‐cardiac tissues have been identified in patients with heart failure (HF). Fatty acid‐binding protein 1 (FABP), also known as liver FABP, is predominantly expressed in the liver. Circulating FABP1 has been proposed to be a sensitive biomarker for liver injury. However, little is known about the potential role of FABP1 as a biomarker for HF. METHODS AND RESULTS: Measurements of serum FABP1 and echocardiography were performed in subjects with compensated HF (n = 162) and control subjects without HF (n = 20). Patients were prospectively followed‐up for a composite outcome of all‐cause mortality or HF hospitalization. Compared with control subjects, levels of FABP1 were elevated in HF patients [7.9 (6.4–11.7) vs. 17.6 (10.4–28.9) ng/mL, P < 0.0001]. There were significant correlations between FABP1 levels and estimated right ventricular systolic pressure and right atrial pressure. During a median follow‐up of 12.0 months, there were 55 primary composite endpoints in the HF cohort. The highest FABP1 tertile was associated with a three‐fold increased risk of the composite outcome compared with the lowest tertile [95% confidence interval (1.46–6.68), P = 0.003], but other conventional hepatobiliary markers did not predict the outcome. After adjusting for age, sex, atrial fibrillation, and N‐terminal pro‐B‐type natriuretic peptide levels, serum FABP1 remained independently associated with the outcome. Adding FABP1 to the model based on clinical factors and N‐terminal pro‐B‐type natriuretic peptide significantly improved the prognostic value (global χ (2) 20.8 vs. 15.5, P = 0.01). CONCLUSION: Serum FABP1 levels are elevated in compensated HF patients, and the magnitude of elevation is independently associated with pulmonary hypertension, right atrial hypertension, and worse clinical outcomes. FABP1 may serve as a new potential biomarker for the assessment of hitherto unrecognized derangement of cardio‐hepatic interaction in HF. John Wiley and Sons Inc. 2021-02-04 /pmc/articles/PMC8006713/ /pubmed/33539661 http://dx.doi.org/10.1002/ehf2.13239 Text en © 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Research Articles Kagami, Kazuki Sunaga, Hiroaki Sorimachi, Hidemi Harada, Tomonari Yoshida, Kuniko Kato, Toshimitsu Kurosawa, Koji Kawakami, Ryo Koitabashi, Norimichi Iso, Tatsuya Adachi, Takeshi Kurabayashi, Masahiko Obokata, Masaru Prognostic impact of elevated fatty acid‐binding protein 1 in patients with heart failure |
title | Prognostic impact of elevated fatty acid‐binding protein 1 in patients with heart failure |
title_full | Prognostic impact of elevated fatty acid‐binding protein 1 in patients with heart failure |
title_fullStr | Prognostic impact of elevated fatty acid‐binding protein 1 in patients with heart failure |
title_full_unstemmed | Prognostic impact of elevated fatty acid‐binding protein 1 in patients with heart failure |
title_short | Prognostic impact of elevated fatty acid‐binding protein 1 in patients with heart failure |
title_sort | prognostic impact of elevated fatty acid‐binding protein 1 in patients with heart failure |
topic | Original Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006713/ https://www.ncbi.nlm.nih.gov/pubmed/33539661 http://dx.doi.org/10.1002/ehf2.13239 |
work_keys_str_mv | AT kagamikazuki prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure AT sunagahiroaki prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure AT sorimachihidemi prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure AT haradatomonari prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure AT yoshidakuniko prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure AT katotoshimitsu prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure AT kurosawakoji prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure AT kawakamiryo prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure AT koitabashinorimichi prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure AT isotatsuya prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure AT adachitakeshi prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure AT kurabayashimasahiko prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure AT obokatamasaru prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure |